electroCore, Inc. (ECOR): Price and Financial Metrics

electroCore, Inc. (ECOR): $1.57

-0.01 (-0.63%)

POWR Rating

Component Grades














  • Sentiment is the dimension where ECOR ranks best; there it ranks ahead of 69.25% of US stocks.
  • ECOR's strongest trending metric is Quality; it's been moving up over the last 31 weeks.
  • ECOR ranks lowest in Quality; there it ranks in the 3rd percentile.

ECOR Stock Summary

  • electroCore Inc's stock had its IPO on June 22, 2018, making it an older stock than merely 8.39% of US equities in our set.
  • ECOR's price/sales ratio is 19.34; that's higher than the P/S ratio of 89.35% of US stocks.
  • electroCore Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -33.88%, greater than the shareholder yield of just 7.68% of stocks in our set.
  • Stocks that are quantitatively similar to ECOR, based on their financial statements, market capitalization, and price volatility, are JFU, SGLB, NCSM, DYAI, and GTHX.
  • Visit ECOR's SEC page to see the company's official filings. To visit the company's web site, go to www.electrocore.com.

ECOR Price Target

For more insight on analysts targets of ECOR, see our ECOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.60 Average Broker Recommendation 1.5 (Moderate Buy)

ECOR Stock Price Chart Interactive Chart >

Price chart for ECOR

ECOR Price/Volume Stats

Current price $1.57 52-week high $3.63
Prev. close $1.58 52-week low $0.77
Day low $1.56 Volume 37,426
Day high $1.60 Avg. volume 2,502,270
50-day MA $1.70 Dividend yield N/A
200-day MA $1.86 Market Cap 76.21M

electroCore, Inc. (ECOR) Company Bio

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is based in Basking Ridge, New Jersey.

ECOR Latest News Stream

Event/Time News Detail
Loading, please wait...

ECOR Latest Social Stream

Loading social stream, please wait...

View Full ECOR Social Stream

Latest ECOR News From Around the Web

Below are the latest news stories about electroCore Inc that investors may wish to consider to help them evaluate ECOR as an investment opportunity.

electroCore to Join Russell Microcap® Index

ROCKAWAY, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap® Index after its 2021 annual reconstitution, effective after the open of trading on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion

Yahoo | June 16, 2021

electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits

ROCKAWAY, NJ, June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program for fiscal years 2019 and 2020. As a result, the Company has received approximately $1.4 million in non-dilutive cash from the sale of these net operating loss (NOL)

Yahoo | June 9, 2021

electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients

ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson’s Disease in Patients with Freezing of Gait” in the journal NPJ Parkinson’s Disease. The paper reports the results of a randomized, double-blind, sham-controlled crossover trial conducted at the Institute

Yahoo | June 2, 2021

35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Summer Solstice - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, June 1, 2021, with company presentations beginning at 9am Eastern Time.

Yahoo | May 27, 2021

electroCore to Present at Investor Conferences in June

ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows: Summer Solstice Best Ideas Conference Date: Tuesday, June 1, 2021Time: 09:30 AM EDTInvestors can register for the conference HERE. LD Micro Invitational XI: Date: Tuesday, June 8, 2020Time: 3:30 PM EDTInvestors can register for the conference HERE. JMP Securities Life Sciences Conference: Date: Thursday, June 17, 2021Time: 12:30 PM EDTInvestors can register for the conference HERE. Dan Goldberger, electroCore’s Chief Executive Officer, and Brian Posner, Chief Financial Officer, will provide an overview of th...

Yahoo | May 26, 2021

Read More 'ECOR' Stories Here

ECOR Price Returns

1-mo -5.42%
3-mo -24.52%
6-mo -2.48%
1-year 79.72%
3-year -92.09%
5-year N/A
YTD 0.64%
2020 -1.89%
2019 -74.60%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0356 seconds.